Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Jim B who wrote (3745)	8/16/1998 2:15:00 PM
From: Profiteer	Read Replies (2) \| Respond to of 5402

Yes sir Jim, This Blood Substitute topic is not going to go away! I'm really feeling good about having Dr. Drees and his Twenty-something plus years of experience on our team. Here is another interested party trying to get into the act! Synthetic Blood International Transfers Perfluorocarbon Development to Southern California KETTERING, OHIO (Aug. 12) BUSINESS WIRE -Aug. 12, 1998--Synthetic Blood International Inc. (SYBD) today announced that it is transferring the development of the company's perfluorocarbon products from Ohio to Southern California. The company recently established a laboratory in Orange County. SYBD's laboratory facilities, which until now have been engaged primarily in research under the leadership of Dr. Leland C. Clark, Jr., have been located near Dayton, Ohio where the company has headquarters. The company recently shifted focus to commercial development of its products and FDA-required testing and has hired key product development staff in Southern California. SYBD will continue to maintain laboratory facilities for its biosensor program and basic research in Ohio. "The opening of a perfluorocarbon product development laboratory in Southern California is a good move for SYBD," said Richard Kiral, Ph.D., vice president of product development and an Orange County, Calif., resident. "It locates appropriate laboratory space with product development teams and results in a significant net reduction in operating costs." SYBD is developing Oxycyte(tm), a fluorocarbon-based blood substitute, Fluorovent(tm), a perfluorocarbon liquid ventilation product, and an implanted glucose biosensor for continuous monitoring of blood glucose in diabetics. SYBD is located in Kettering, Ohio and has a West Coast office in Irvine, Calif. The company's stock is traded on the OTC Electronic Bulletin Board, symbol SYBD. The company has an Internet Web site at www.sybd.com and an e-mail address of sybd@siscom.net. -0- ktbh/sd* sf/sd CONTACT: Synthetic Blood International Inc.